Call us
Tesamorelin Acetate

Tesamorelin Acetate

Tesamorelin acetate, also known under the branded name of Egrifta, is a manufactured form of growth-hormone-releasing hormone (GHRH) predominantly used in the treatment of HIV-associated lipodystrophy. Tesamorelin acetate is a manufactured peptide comprised of all 44 amino acids of human GHRH as well as a trans-3-hexenoic acid group. Structurally, tesamorelin acetate is created through the attachment of a hexenoyl moiety, which is a C6 chain holding a double bond at position 3, to the accompanying tyrosine residue at the N-terminal of the molecule. Tesamorelin acetate stimulates the body's growth hormone secretion, and thus increases and helps to temporarily maintain IGF-1 and IGFBP-3 levels.

Some Potential Benefits:

  • Treatment of HIV-Associated Lipodystrophy

Dosing

Tesamorelin acetate is delivered as a sterile, preservative-free lyophilized powder designed for subcutaneous injection. Reconstitution must occur before use. Reconstitute with sterile water for injection, USP. Vials typically contain 2 mg of tesamorelin as the free base (2.2 mg tesamorelin acetate, anhydrous) and a percentage of inactive ingredient— mannitol, USP. The generally recommended dose is 2 mg injected subcutaneously once a day. Decisions regarding a particular patient's individual dosage will be strictly predicated upon the patient's current medical/health status, current medications, medical history, family history, age, weight, and gender.

Side Effects Note:

Some patients may experience some mild or severe side effects listed below.

  • Increase in Thirst
  • Swelling (hands, ankles, feet)
  • Stiffness (muscles and joints)
  • Wrist Pain
  • Wrist Numbness
  • Pain (muscles and joints)
  • Pain (arms and legs)
  • Fluttering in Chest
  • Pounding Heartbeat
  • High Blood Sugar
  • Numbness and/or Tingling (hands and/or fingers)
  • "It is rare to find health professionals who are so willing to educate the patient on what they need to know."

    Clair C. | West Hollywood, CA